Jefferies specialty pharmaceuticals report

According to Jefferies & Co., Inc. analyst David Windley, for the week ended April 28, Lidoderm, Lexapro and Provigil, the largest drugs for their respective companies, Endo Pharmaceuticals (Buy), Forest Laboratories (Hold) and Cephalon (Hold), remain on track to meet Jefferies' forecast. Endo's Oxycodone ER is ahead of the analyst's expectations in light of competition from other generics. Connetics' (Hold) portfolio is trailing Jefferies' forecast, as are ISTA Pharmaceuticals' (Hold) Xibrom, and Istalol.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.